Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder later this quarter and ongoing Phase III work in generalized anxie
MarketBeat ·